TME-aligned 3D Solid Tumor Models for Bispecific Antibodies
Vivia’s ex vivo TMEaligned 3D model offers a very well controlled environment which can recreate the complexity of the TME and generate a reliable platform for studies on the effects of Bispecific Antibodies (BsAb) in Solid Tumors.

Vivia’s 3D model recapitulates original tumor microenvironment and promotes naïve behavior of tumor and immune cells. Once embedded in this native-like matrix, T-cells and tumor cells interact brought into proximity by BsAb (or multispecific antibodies).

Overall Activity BsAb EGFRxCD3 in Autologous TILs & Samples

  • Both tumor cell killing, and T cell activation occur at the same EC50.
  • All three T Cell related parameters (right) overlap, though with different cell counts.
Figura 1 Overall Activity Bispecific Antibody EGFRxCD3
Figure 1. Absolute counts for each cell subset shown before superposed

Combinations with Other IO Drugs like PD1 enhance T Cell activation and tumor killing

Figura 2 Bispecific Antibodies Combination With Immune Checkpoint Inhibitors
Figure 1. Ovarian Cancer with Autologous TILs (E:T Ratio 1:2)
  • PD1 alone does not active T cells or induce tumor cell kill
  • We can also evaluate TRISPECIFIC ANTIBODIES ex vivo activity

TME-Aligned 3D Model for Immune Oncology Effects

Figura 3 TME Aligned 3D Model For Immune Oncology Effects

Analysis Leverage Power of Multiparametric Flow Cytometry After Disaggregating 3D Assays

Figura 4 Multiparametric Flow Cytometry After Disaggregating 3D Assays

Highlights

  • Validated in 14 years at big pharma with clinical trials & mouse models for targeted and cytotoxic drugs.
  • Best models for IO drugs such as BsAbs:
  • Immunosuppressor TME lowers T cell activation
  • Key differentiating factor among 3D models
  • Suitable for Trispecific Antibodies as well
  • Disaggregating cells for flow cytometry enables powerful assays
  • Sorting resistant or other relevant cell subsets
  • Molecular profiling: we can identify the molecular basis of resistance to a BsAb in tumor and T cells
  • Access to cell lines & patient samples
  • Including autologous TILs for IO assays
  • Assays suitable for carcinomas
Click Here